The FDA has approved Delcath System's IND application for a Phase II trial on the Hepzato Kit as an add-on treatment for liver-dominant mCRC. The trial aims to evaluate its efficacy and safety, with results expected by 2027-2028.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing